About
Scribe Therapeutics Inc.
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression.
It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing.
Scribe Therapeutics Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Change from offer price to today
Live Market Snapshot
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:SCTX
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-07-30 | $18.79 | $22.66 | $18.67 | $20.40 | $20.40 | +1.61 | 147,663 |
| 2026-07-29 | $18.05 | $19.17 | $17.81 | $18.36 | $18.36 | +0.31 | 325,110 |
| 2026-07-28 | $18.00 | $18.89 | $17.50 | $18.06 | $18.06 | +0.06 | 428,608 |
| 2026-07-27 | $21.48 | $22.75 | $17.31 | $18.97 | $18.97 | -2.51 | 419,109 |
| 2026-07-24 | $25.00 | $25.49 | $21.00 | $21.65 | $21.65 | -3.35 | 990,795 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| SCHEDULE 13D | Jul 30, 2026 | Filing |
| SCHEDULE 13D | Jul 30, 2026 | Filing |
| SCHEDULE 13D | Jul 29, 2026 | Filing |
| 8-K | Jul 27, 2026 | Current Report |
| S-8 | Jul 27, 2026 | Securities to be offered to employees in employee benefit plans |
| 424B4 | Jul 27, 2026 | Prospectus |
| FWP | Jul 24, 2026 | Free Writing Prospectus |
| EFFECT | Jul 23, 2026 | Notice of Effectiveness |
| S-1MEF | Jul 23, 2026 | Registration adding securities to prior Form S-1 registration |
| CERT | Jul 22, 2026 | Certification by an exchange approving securities for listing |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Benjamin L. Oakes, Ph.D.
President, Chief Executive Officer and Director
Svetlana Lucas, Ph.D.
Chief Business Officer
David L. Parrot, M.B.A.
Chief Financial Officer
James Watson, M.B.A.
Director
Behzad Aghazadeh, Ph.D.
Director
Carl L. Gordon, Ph.D., CFA
Director
